Zusammenfassung
Zwei entscheidende Erkenntnisse der letzten 15 Jahre haben zu einem Wandel in der Therapie primärer Magenlymphome geführt: Studien haben gezeigt, dass die Operation keine therapeutische Option mehr ist und dass bei Marginalzonenlymphomen im Stadium I mit positivem Nachweis von Helicobacter pylori (H.p.) eine antibiotische Behandlung in der überwiegenden Zahl der Fälle zu einer Heilung des Lymphoms führt. Für indolente Lymphome in den Stadien I und II zeigen die Daten der Deutschen Studiengruppe Gastrointestinale Lymphome, dass die Strahlentherapie mit 40 Gy im Tumorbereich zu einer Kontrolle des Lymphoms zu über 95% führt. Standards für lokalisierte aggressive Non-Hodgkin-Lymphome bzw. Lymphome in den Stadien III und IV sind noch nicht ausreichend definiert.
Abstract
There have been two major findings which have influenced the treatment strategies of primary gastric lymphomas during the last 15 years. In prospective studies it was shown that primary resection of a lymphoma was no longer a treatment option and that in the majority of cases antibiotic treatment of Helicobacter pylori in stage I marginal zone lymphoma could induce remission and lead to a cure. From the data of three consecutive studies on localized indolent lymphoma the German Study Group on Gastrointestinal Lymphoma concluded that in over 95% of patients radiotherapy led to control of the tumor using doses of 40 Gy while reducing the volume to involved field at least in stage I. In contrast standards for treating localized aggressive lymphomas and advanced lymphomas in stages III and IV have not yet been sufficiently defined.
Literatur
Isaacson P, Wright DH (1983) Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52:1410–1416
Koch P, Valle F del, Berdel WE et al (2001) Primary gastrointestinal non-Hodgkin’s lymphoma I: Anatomical and histological distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study (GIT NHL 01/92). J Clin Oncol 19:3861–3873
Swerdlow SH, Campo E, Harris et al (Hrsg) (2008) WHO classifications of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
Hussell T, Isaacson PG, Crabtree JE, Spencer J (1993) The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 342:571–574
Wotherspoon AC, Doglioni C, Diss TC et al (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575–577
Floßbach L, Kestler HA, Gress TM, Möller P, Barth TFE (2010) Current aspects of the pathology and differentiation of extranodal marginal zone B-cell lymphoma, MALT-Type, and gastrointestinal diffuse large B-cell lymphoma. Z Gastroenterol 48:833–838
Musshoff K (1977) Klinische Stadieneinteilung der Nicht-Hodgkin-Lymphome. Strahlentherapie 153:218–221
Koch P, Valle F del, Berdel WE et al (2001) Primary gastrointestinal non-Hodgkin’s lymphoma II: Combined surgical and conservative or conservative management only in localized gastric lymphoma. Results of the prospective German multicenter study (GIT NHL 01/92). J Clin Oncol 19:3874–3883
Aviles A, Nambo MJ, Neri N et al (2004) The role of surgery in primary gastric lymphoma. Results of a controlled clinical trial. Ann Surg 240:44–50
Aviles A, Nambo MJ, Neri N, Talavera A, Cleto S (2005) Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 22:57–62
Koch P, Probst A, Berdel WE et al (2005) Treatment results in localized primary gastric lymphoma: Data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 28:7050–7059
Fischbach W, Malfertheiner P, Hoffmann JC et al (2009) S3-guideline „helicobacter pylori and gastroduodenal ulcer disease“ of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021/001. Z Gastroenterol 47:1230–1263
Koch P (2010) Gastric Marginal Zone Lymphoma (MZoL): A primary systemic disease? Onkologie 33(Suppl 6; abstract V5):1
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Koch, P., Liersch, R. Therapie primärer Magenlymphome. Onkologe 17, 814–817 (2011). https://doi.org/10.1007/s00761-011-2130-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-011-2130-9